Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis

被引:47
作者
Stompór, TP
Pasowicz, M
Sulowicz, W
Dembinska-Kiec, A
Janda, K
Wójcik, K
Tracz, W
Zdzienicka, A
Konieczynska, M
Klimeczek, P
Janusz-Grzybowska, E
机构
[1] Jagiellonian Univ, Fac Med, Dept Nephrol, PL-31501 Krakow, Poland
[2] Jagiellonian Univ, Fac Med, Dept Clin Biochem, PL-31501 Krakow, Poland
[3] Jagiellonian Univ, Fac Med, John Paul II Hosp, Dept Cardiac & Vasc Dis, Krakow, Poland
关键词
coronary artery calcification (CAC); calcification score; atherosclerosis; phosphates; calcium x phosphate product (Ca x P);
D O I
10.1053/j.ajkd.2004.05.029
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Accelerated vascular calcification is an important cause of excess mortality inpatients on dialysis therapy. The aim of the study was to evaluate the trends in coronary artery calcification (CAC) score (CaSc) during a 1-year period in a group of stable peritoneal dialysis (PD) patients and identify factors that may be associated with CaSc changes. Methods: Sixty-one stable patients (28 women, 33 men) on PD therapy with a mean age of 50.4+/-13.6 years were included. Forty-seven patients survived the entire study period on PD therapy and were suitable for the final analysis. CaSc was assessed at baseline and after 12 months by using multislice spiral computed tomography. Proinflammatory cytokines (interleukin-6, tumor necrosis factor-alpha [TNF-alpha]), acute-phase proteins (C-reactive protein [CRP], fibrinogen), calcium-phosphate balance, and lipid profile were assessed at baseline and after 6 and 12 months. Results: Median CaSc was 22.6 Agatston units (range, 0 to 5,502.8 Agatston units) at baseline and increased to 84 Agatston units (range, 0 to 5,001.3 Agatston units) at a 1-year follow-up (P<0.05). In the entire group of patients, 3 subgroups were identified: patients with progression (n=21; P=0.02 for the difference between initial versus follow-up CaSc), patients with regression (n=12; P=0.05), and subjects without change in CaSc after 1 year (n=14). Patients without progression showed no calcifications at baseline and follow-up and were younger, less overweight, and characterized by significantly lower mean TNF-alpha, leptin, and CRP levels during 1 year compared with both progressors and regressors. Mean serum phosphate and calcium x phosphate product (Ca x P) values were gradually increasing from regressors through the no-calcification group to progressors (P<0.01 for phosphate levels, P<0.02 for Ca x P product). Significant correlations were found between changes in CaScs and mean values for phosphate (R=0.44; P<0.0005) and Ca x P product (R=0.38; P<0.005). Conclusion: Chronic nonspecific inflammation does not directly attribute to progression in CaScs. Calcium-phosphate balance abnormalities appear to be the only important factors promoting CAC, although a permissive or promoting role of inflammation cannot be ruled out.
引用
收藏
页码:517 / 528
页数:12
相关论文
共 41 条
[1]   QUANTIFICATION OF CORONARY-ARTERY CALCIUM USING ULTRAFAST COMPUTED-TOMOGRAPHY [J].
AGATSTON, AS ;
JANOWITZ, WR ;
HILDNER, FJ ;
ZUSMER, NR ;
VIAMONTE, M ;
DETRANO, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (04) :827-832
[2]   End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? [J].
Arici, M ;
Walls, J .
KIDNEY INTERNATIONAL, 2001, 59 (02) :407-414
[3]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[4]   Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].
Braun, J ;
Oldendorf, M ;
Moshage, W ;
Heidler, R ;
Zeitler, E ;
Luft, FC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401
[5]   Coronary artery calcium determined by electron beam computed tomography for predicting angiographic coronary artery disease in moderate- to high-risk Chinese patients [J].
Chen, LC ;
Ding, PYA ;
Chen, JW ;
Wu, MH ;
Liu, JC ;
Lan, GY ;
Chern, MS ;
Chang, CY ;
Chang, MS .
CARDIOLOGY, 2001, 95 (04) :183-189
[6]   Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Raggi, P .
KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252
[7]  
*EBPG EXP GROUP RE, 2002, NEPHROL DIAL TRAN S4, V17, pS24
[8]  
FERNANDEZREYES MJ, 1995, NEPHROL DIAL TRANSPL, V10, P2090
[9]   BONE-DISEASE AND ALUMINUM - PATHOGENIC CONSIDERATIONS [J].
GOODMAN, WG .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1985, 6 (05) :330-335
[10]   Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis [J].
Goodman, WG ;
Goldin, J ;
Kuizon, BD ;
Yoon, C ;
Gales, B ;
Sider, D ;
Wang, Y ;
Chung, J ;
Emerick, A ;
Greaser, L ;
Elashoff, RM ;
Salusky, IB .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1478-1483